A number of stocks jumped in the afternoon session after the major indices popped (Nasdaq +3.4%, S&P 500 +2.5%) in response to the positive outcome of U.S.-China trade negotiations, as both sides agreed to pause some tariffs for 90 days, signaling a potential turning point in ongoing tensions. This rollback cuts U.S. tariffs on Chinese goods to 30% and Chinese tariffs on U.S. imports to 10%, giving companies breathing room to reset inventories and supply chains.
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street.
Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the medical devices & supplies - diversified stocks, including Neogen (NASDAQ:NEOG) and its peers.
Insiders are buying stock in 2025, and the purchases are not limited to a single market cap, sector, or industry. Analysts see deep value in these stocks.
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer.
However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.
Wall Street has set ambitious price targets for the stocks in this article.
While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Neogen Corporation (NASDAQ: NEOG) stock rose after announcing the $130 million sale of its global cleaners and disinfectants business to Kersia Group. The divestiture allows Neogen to focus on core food safety diagnostics while reducing debt and improving margins.
Healthcare product and device company Abbott Laboratories (NYSE:ABT)
will be announcing earnings results tomorrow before the bell. Here’s what to look for.
Looking for insights into the US markets in the middle of the day on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Life sciences company Neogen (NASDAQ:NEOG) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.4% year on year to $221 million. The company’s full-year revenue guidance of $895 million at the midpoint came in 1.7% below analysts’ estimates. Its non-GAAP profit of $0.10 per share was 13% below analysts’ consensus estimates.
